ADAPTIMMUNE THERAPTCS ADR by Adaptimmune Therapeutics plc (ADAPY) Expected Move

Tracking the ADAPY expected move helps you see how far ADAPTIMMUNE THERAPTCS ADR by Adaptimmune Therapeutics plc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. ADAPTIMMUNE THERAPTCS ADR by Adaptimmune Therapeutics plc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the ADAPY expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For ADAPY, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The ADAPY expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks ADAPTIMMUNE THERAPTCS ADR by Adaptimmune Therapeutics plc is unlikely to go.

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).

It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the ADAPY expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The ADAPTIMMUNE THERAPTCS ADR by Adaptimmune Therapeutics plc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about ADAPY.